Navigation Links
Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Date:10/23/2007

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

"We are really looking forward to treating patients in this trial," said Principal Investigator Dr. James Spicer. "The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to stan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., REYKJAVIK,Iceland,November24/PRNewswire-FirstCa...ncedthatithasreceivednoticefrom,theNasdaqStockMark...ndedasofNovember30,2009andaForm25-NSEwillbefiledwi...ovedeCODE,scommonstock,fromlistingonNasdaq,unlesst...tionsPanel.Thecompanyhasfiledsuchanappeal,which,wi...
(Date:11/24/2009)..., REYKJAVIK,Iceland,November24/PRNewswire-FirstCa...ncedtheapprovalofallofits,"firstday"motionsbytheU....kruptcyCourt").deCODElastweekfiledavoluntarypetiti...tcyCodewiththe,BankruptcyCourt. , Theordersis...tooperateitsbusinessduringtheChapter11proceedings....
(Date:11/24/2009)..., SHANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiBiola...tion(SFDA)hasapprovedthe,investigationalnewdrugapp...nnovativeinsulinformulationtotreatdiabetes.ThisIND...icalstudy. , Diabetesisadisordercharacteristi...ionsofdiabetesoftenresultinseveremicro-and,macro-v...
(Date:11/24/2009)... ,Primaryefficacyendpointhasbeenmetforpatientswit..., QUEBECCITY,Nov.24/PRNewswire-FirstCall/-AEterna...aglobalbiopharmaceuticalcompanyfocusedonendocrinet...tafromaPhase2studywithitstargetedcytotoxicpeptidec...vancedorrecurrentendometrialcancer.Inapersonalized...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...nd Launched - Screening Closed in First Phase II... May 13 Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ...er ended March 31, 2008., Total revenues for the ...mpared to $14.1 million for the quarter ended Marc...) net sales for the first quarter of 2008,increase...
...ed in the Quarter Production Increases t...ce Expands to Cover All 50 States, BEDFORD, Mass....leader in wearable insulin pump technology with it...unced financial results for,the first quarter ende...venue increased 232% to $6.7 million,compared to $...
...en Sergeant Heather Maddy of the,325th Combat Supp...Incorporated (VTI) of Nashua, NH inquiring about a...nt called a Surgical Doppler for her operating,roo...days -- free of,charge., "I would like to let you...days ago!" SGT Maddy wrote. "And we cannot thank y...
Other Biology Technology:Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 2Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 3Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 4Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 5Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 6Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 7Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results 8Insulet Reports First Quarter 2008 Results 2Insulet Reports First Quarter 2008 Results 3Insulet Reports First Quarter 2008 Results 4Insulet Reports First Quarter 2008 Results 5Insulet Reports First Quarter 2008 Results 6Insulet Reports First Quarter 2008 Results 7Serving Those Who Serve Our Country: Medical Device Company Answers the Call of a U.S. Combat Hospital in Iraq 2
(Date:11/23/2009)..., BIRMINGHAM, Ala. A new study by University of ... body-mass index (BMI) and co-existing medical con...d survival observed among African-Americans compar...tudy is published online Nov. 23 in Cancer , a jo...ing indicates that although BMI and co-morbidity a...
(Date:11/23/2009)...HAMPAIGN, Ill. Two new studies reveal in unpreced... molecules to assemble new proteins and guide them... studies used molecular dynamics flexible fitting ...with two prominent molecular partners. , The fi... of Sciences , concerns the intimate signaling bet...
(Date:11/23/2009)...ORVALLIS, Ore. A string of recent discoveries abo...enewed interest in this multi-purpose nutrient, in...o are deficient in it, spurred research and even l...c." , On issues ranging from the health of your ...ven vulnerability to influenza, vitamin D is now s...
Breaking Biology News(10 mins):Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3Fewer Shots Could Still Protect Kids From Pneumonia 50989 1Fewer Shots Could Still Protect Kids From Pneumonia 50989 2New Clues to Race Gap in Breast Cancer Outcomes 50984 1New Clues to Race Gap in Breast Cancer Outcomes 50984 2New Clues to Race Gap in Breast Cancer Outcomes 50984 3Video 3A Perot Systems Unveils Series of Healthcare Video Case Studies 50979 1Video 3A Perot Systems Unveils Series of Healthcare Video Case Studies 50979 2
...and the Foundation for Innovative New Diagnostics ...oday confirming their agreement to work in partner...s disease diagnosis and service integration in res...llaboration between the ASM and FIND will focus on...se diagnosis in resource-poor nations, providing n...
... look forward to new, novel forms of their favouri...l genetic data which fruit breeders say will help ...health properties and exciting colours and flavour...ce company HortResearch and listed New Zealand bio...oration Limited announced today that they would co...
...e within the eye and dispense medication according...eloped by biomedical engineers at UC Davis. , Tin...ering, and postdoctoral researcher Hailin Cong sta...PDMS). They developed a method for placing powdere...te conductive wires. The silver also has antimicro...
Other Biology News:ASM and FIND to partner on strengthening infectious disease diagnosis in developing nations 2Genetic data promises new future for kiwi fruit 2Genetic data promises new future for kiwi fruit 3
...d Non-Radioactive Translation Detection Systems al...zed in vitro. Using these systems, biotinylated ly...ns during translation, eliminating the need for la...amino acids. This biotinylated lysine is added to ...
Dulbecco's Phosphate Buffered Saline (DPBS) from Sigma-Aldrich
Illumina Standard Data Analysis Report from Asuragen, Inc.
... value of your microarray data using Asuragens bio...ed from consultation to extensive data analysis us...tise in combination with the Gene Expression Profi...ts., ,Normalization and basic statistical anal...
Biology Products: